Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs American Water Works Company Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while American Water Works Company Inc trades at $133.97 (market cap $26.33B). The key difference: American Water Works Company Inc is far larger — about 5.9× ACADIA Pharmaceuticals Inc.'s market cap, and American Water Works Company Inc pays a 2.66% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AWK | |
|---|---|---|
Market Cap | $4.49B | $26.33B |
Sector | Health | Utilities |
52-Week High | $28.06 | $147.00 |
52-Week Low | $20.06 | $121.13 |
Enterprise Value | $3.69B | $41.89B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AWK trades at $134.82, down 1.49% today, near the consensus price target of $134.50. The stock shows a bullish technical trend with strong moving averages, while recent earnings have been mixed with two misses in the last three quarters. Revenue grew to $5.14B in 2025, with a net income margin of 21.17%, and the company continues strategic acquisitions and infrastructure investments, as seen in recent news (PRNewsWire, June 30, 2026).
Outlook remains stable with analyst consensus leaning buy (46.66% buy ratings), but risks include high debt levels and regulatory pressures. The stock offers steady growth potential through capital investments, though margin pressures and interest expenses could limit upside. Investors should weigh the defensive utility sector appeal against valuation multiples like a P/E of 23.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
